Lupin in focus as EU Court upholds fine in Perindopril litigation

Lupin announced that the General Court of the European Union has delivered its judgment concerning Lupin's and other companies appeal against the European Commission's (EC) 2014 decision in the Perindopril litigation. The General Court upheld the EC's decision holding Lupin liable to pay a fine of EUR 40 million. Lupin will study the General Court's judgment and evaluate further course of action. The announcement was made after market hours yesterday, 12 December 2018.

DLF said that the company's board of directors has considered and approved offering upto 17.30 crore equity shares in one or more tranches by way of private placement, including Qualified Institutions Placement (QIP). The announcement was made after market hours yesterday, 12 December 2018.

Indian Oil Corporation's board meets today to consider and approve buyback of equity shares and interim dividend.

Strides Pharma Science (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food & Drug Administration (US FDA). Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP. The announcement was made after market hours yesterday, 12 December 2018.

Infibeam Incorporation said that the meeting of the board of directors of the company is scheduled on 17 December 2018 to consider and approve examine and evaluate the feasibility of and options for strategic growth opportunities of the business verticals and subsidiaries of the company. The announcement was made after market hours yesterday, 12 December 2018.

Powered by Capital Market - Live News